

28 February 2019

N4 Pharma Plc

("N4 Pharma" or the "Company")

Total Voting Rights

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments, announces the Company's issued ordinary share capital as at the date of this announcement comprises 101,462,537 ordinary shares, with one voting right each. The Company does not hold any ordinary shares in treasury. Therefore, the total number of ordinary shares and voting rights in the Company is 101,462,537.

The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

N4 Pharma Plc

Nigel Theobald, CEO

Via Alma PR

Allenby Capital Limited

James Reeve/Asha Chotai

Tel: +44(0)203 328 5656

Alma PR

Josh Royston

Helena Bogle

Tel: +44(0)778 090 1979

Tel: +44(0)758 021 6203

About N4 Pharma plc

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments using its unique silica nanoparticle delivery system called Nuvec®.

Nuvec® has already shown to be capable of loading and delivering mRNA and pDNA into cells to the required level needed to generate an immune

response capable of strong antibody production.

N4 Pharma's business model is to partner with companies developing novel antigens for vaccines and cancer treatments to use Nuvec® as the delivery vehicle to deliver their antigen into cells to express the protein needed for the required immunity. As these products progress through pre-clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

TVRCKODPQBKDABB